ACRV
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Acrivon advanced ACR-2316 into randomized dose expansion in its ongoing Phase 1/2 studyAug 6, 2026
- Acrivon Therapeutics announced positive ACR-368 Phase 2b data and EU expansionJan 8, 2026
- Acrivon Therapeutics to give clinical update on ongoing Phase 2b ACR-368 studies, planned Phase 3 trial, initial ACR-2316 data, and other AP3 pipeline programs via webcastJan 6, 2026
- Acrivon Therapeutics highlights its powerful generative phosphoproteomics AP3 platform with compelling preclinical data for ACR-2316 with three presentations at the upcoming AACR-NCI-EORTC International ConferenceOct 23, 2025